CRYSVITA (burosumab injection) CRYSVITA (burosumab injection)

ULTRACARE: ASSISTANCE IN GAINING ACCESS TO CRYSVITA (Burosumab Injection)

CRYSVITA is a treatment that targets FGF23, the underlying cause of X-linked hypophosphatemia (XLH) and hypophosphatemia in tumor-induced osteomalacia (TIO)

Assistance in Gaining Access to Crysvita

UltraCare services are designed to help facilitate patient access to CRYSVITA treatment.

Enrolling in UltraCare may help you to:

  • Understand a patient's Insurance Coverage
  • Access patient resources in the Patient Support Programs

Download a CRYSVITA Patient Enrolment Form to start the enrolment process

Fill out the form with your patient and fax it to 1-833-592-2273 (CARE). Please note that a completed form is required for your enrolment.



For additional support, please call 1-833-388-5872 (U-LTRA).

LESS

Indication and clinical use

CRYSVITA™ (Burosumab Injection) is indicated for the treatment of

  • X-linked hypophosphataemia (XLH) in adult and pediatric patients 6 months of age and older
  • Fibroblast growth factor 23 (FGF23)–related hypophosphataemia in tumor-induced osteomalacia (TIO) associated with tumors that cannot be curatively resected or localized in adult patients.
  • Treatment should be initiated and monitored by a health professional experienced in the management of patients with metabolic bone diseases.

    Safety and efficacy in pediatric populations with TIO and geriatric populations with XLH and TIO have not been established.

    Please see Product Monograph for safety information discussing:

  • Contraindications in patients who are hypersensitive to this drug or any of its ingredients, in patients who take oral phosphate and active vitamin D analogues (calcitriol or alfacalcidol), in patients with a serum phosphorus within or above the normal range for age and in patients with severe renal impairment or end stage renal disease.
  • Relevant warnings and precautions about hyperphosphataemia and risk of ectopic mineralization, injection site reactions, vitamin D decrease, driving and operating machinery, hypersensitivity reactions, immunogenicity, monitoring and laboratory tests, fertility, pregnancy and breast-feeding.

Please click here for the Product Monograph, which also includes important information related to adverse reactions and dosing. The Product Monograph is also available by calling 1-833-388-5872.

Indication and clinical use

CRYSVITA™ (Burosumab Injection) is indicated for the treatment of X-linked hypophosphataemia (XLH) in adult and pediatric patients 6 months of age and older.

Treatment should be initiated and monitored by a health professional experienced in the management of patients with metabolic bone diseases.

Safety and efficacy in geriatric populations have not been established.

    Please see Product Monograph for safety information discussing:

  • Contraindications in patients who are hypersensitive to this drug or any of its ingredients, in patients who take oral phosphate and active vitamin D analogues (calcitriol or alfacalcidol), in patients with a serum phosphorus within or above the normal range for age and in patients with severe renal impairment or end stage renal disease.
  • Relevant warnings and precautions about hyperphosphataemia and risk of ectopic mineralization, injection site reactions, vitamin D decrease, driving and operating machinery, hypersensitivity reactions, immunogenicity, monitoring and laboratory tests, fertility, pregnancy and breast-feeding.

Please click here for the Product Monograph, which also includes important information related to adverse reactions and dosing. The Product Monograph is also available by calling 1-833-388-5872.

For additional information and questions about medical information or medical affairs, please contact Ultragenyx Medical Affairs at 1-833-388-5872 (U-LTRA).

Canadian Site: CRYSVITA Access Support | UltraCare for Canadian Health Professionals Treating X-linked Hypophosphataemia (XLH)